Review: Novel targets in the management of pneumonia

Therapeutic Advances in Respiratory Disease

Volumn 2, Issue 6, 2008, Pages 387-400

  Díaz, Luis A ^a   Mortensen, Eric M ^b   Anzueto, Antonio ^c   Restrepo, Marcos I ^b  

^a HOSPITAL DE SAN JOSÉ   (Colombia)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

community acquired infections; intensive care unit; pneumonia; therapeutics

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DROTRECOGIN; HYDROCORTISONE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; SULTAMICILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; BACTERIUM ISOLATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; INTENSIVE CARE UNIT; LOW DRUG DOSE; LUNG FUNCTION TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTECTION; PSEUDOMONAS AERUGINOSA; PUBLIC HEALTH; REVIEW; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DRUG DELIVERY SYSTEMS; HUMANS; INTENSIVE CARE; PNEUMONIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 68749094400     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465808098694     Document Type: Review

References (120)

1. CDC (1999) National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 27: 520-532.
2. Idsa/Ats (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416.
3. Abraham, E., Laterre, P.F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B.L. et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332-1341.
4. Administration (2001) Xigris: drotrecogin alfa (activated): PV 3420 AMP Rockville, MD: Food and Drug Administration.
5. Amato, M.B., Barbas, C.S., Medeiros, D.M., Magaldi, R.B., Schettino, G.P., Lorenzi-Filho, G. et al. (1998) Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 338: 347-354.
6. Amsden, G.W. (2005) Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55: 10-21.
7. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J. and Pinsky, M.R. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310.
8. Angus, D.C., Marrie, T.J., Obrosky, D.S., Clermont, G., Dremsizov, T.T., Coley, C. et al. (2002) Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 166: 717-723.
9. Antunes, G., Evans, S.A., Lordan, J.L. and Frew, A.J. (2002) Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 20: 990-995.
10. Arancibia, F., Bauer, T.T., Ewig, S., Mensa, J., Gonzalez, J., Niederman, M.S. et al. (2002) Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 162: 1849-1858.
11. Baddour, L.M., Yu, V.L., Klugman, K.P., Feldman, C., Ortqvist, A., Rello, J. et al. (2004) Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170: 440-444.
12. Bartlett, J.G., Dowell, S.F., Mandell, L.A., File Jr, T.M., Musher, D.M. and Fine, M.J. (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31: 347-382.
13. Benenson, R., Magalski, A., Cavanaugh, S. and Williams, E. (1999) Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad Emerg Med 6: 1243-1248.
14. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A. et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709.
15. Blot, S.I., Rodriguez, A., Sole-Violan, J., Blanquer, J., Almirall, J. and Rello, J. (2007) Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 35: 2509-2514.
16. Bodi, M., Rodriguez, A., Sole-Violan, J., Gilavert, M.C., Garnacho, J., Blanquer, J. et al. (2005) Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 41: 1709-1716.
17. Capelastegui, A., Espana, P.P., Quintana, J.M., Areitio, I., Gorordo, I., Egurrola, M. et al. (2006) Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 27: 151-157.
18. Capelastegui, A., Espana, P.P., Quintana, J.M., Gorordo, I., Ortega, M., Idoiaga, I. et al. (2004) Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 39: 955-963.
19. Cazzola, M., Blasi, F., Centanni, S., Donner, C.F. and Allegra, L. (2001) Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections. Pulm Pharmacol Ther 14: 367-381.
20. Cazzola, M. and Saltini, C. (2005) Novel approaches to the treatment of bacterial lower respiratory tract infections: introduction. Respiration 72: 7-8.
21. Cheng, A.C., Stephens, D.P. and Currie, B.J. (2007) Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev: Apr 18(2): CD004400.
22. Clark, L.C. and Davis, C.W. (2000) Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. Am J Health Syst Pharm 57(suppl.3): S10-13.
23. Confalonieri, M., Urbino, R., Potena, A., Piattella, M., Parigi, P., Puccio, G. et al. (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171: 242-248.
24. Cordero, E., Pachon, J., Rivero, A., Giron, J.A., Gomez-Mateos, J., Merino, M.D. et al. (2000) Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am J Respir Crit Care Med 162: 2063-2068.
25. Dale, D.C., Liles, W.C., Summer, W.R. and Nelson, S. (1995) Review: granulocyte colony-stimulating factor-role and relationships in infectious diseases. J Infect Dis 172: 1061-1075.
26. Dean, N.C., Silver, M.P., Bateman, K.A., James, B., Hadlock, C.J. and Hale, D. (2001) Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 110: 451-457.
27. Dehoux, M.S., Boutten, A., Ostinelli, J., Seta, N., Dombret, M.C., Crestani, B. et al. (1994) Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 150: 710-716.
28. Dellinger, R.P., Levy, M.M., Carlet, J.M., Bion, J., Parker, M.M., Jaeschke, R. et al. (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36: 296-327.
29. Deng, J.C., Tateda, K., Zeng, X. and Standiford, T.J. (2001) Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts. Infect Immun 69: 6382-6390.
30. Dhainaut, J.F., Laterre, P.F., Janes, J.M., Bernard, G.R., Artigas, A., Bakker, J. et al. (2003) Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Int Care Med 29: 894-903.
31. Dremsizov, T., Clermont, G., Kellum, J.A., Kalassian, K.G., Fine, M.J. and Angus, D.C. (2006) Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest 129: 968-978.
32. Dresser, L.D., Niederman, M.S. and Paladino, J.A. (2001) Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 119: 1439-1448.
33. Eisner, M.D., Thompson, T., Hudson, L.D., Luce, J.M., Hayden, D., Schoenfeld, D. et al. (2001) Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 164: 231-236.
34. Ely, E.W., Laterre, P.F., Angus, D.C., Helterbrand, J.D., Levy, H., Dhainaut, J.F. et al. (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31: 12-19.
35. Ewig, S., de Roux, A., Bauer, T., Garcia, E., Mensa, J., Niederman, M. et al. (2004) Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 59: 421-427.
36. Ewig, S., Kleinfeld, T., Bauer, T., Seifert, K., Schafer, H. and Goke, N. (1999) Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J 14: 370-375.
37. Ewig, S., Ruiz, M., Mensa, J., Marcos, M.A., Martinez, J.A., Arancibia, F. et al. (1998) Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 158: 1102-1108.
38. Falagas, M.E., Siempos, II and Vardakas, K.Z. (2008) Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8: 53-66.
39. Fernandez-Serrano, S., Dorca, J., Coromines, M., Carratala, J., Gudiol, F. and Manresa, F. (2003) Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 10: 813-820.
40. File Jr, T.M., Tan, J.S. and Plouffe, J.F. (1998) The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 12: 569-592, vii.
41. Fine, M.J., Auble, T.E., Yealy, D.M., Hanusa, B.H., Weissfeld, L.A., Singer, D.E. et al. (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336: 243-250.
42. Fine, M.J., Smith, M.A., Carson, C.A., Mutha, S.S., Sankey, S.S., Weissfeld, L.A. et al. (1996) Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275: 134-141.
43. Fogarty, C., Siami, G., Kholer, R., File Jr, T.M., Tennenberg, A.M., Olson, W.H. et al. (2004) Multicenter, open label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 38: S16-23.
44. Fogarty, C.M., Greenberg, R.N., Dunbar, L., Player, R., Marrie, T.J., Kojak, C.M. et al. (2001) Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clin Ther 23: 425-439.
45. Francis, J.S., Doherty, M.C., Lopatin, U., Johnston, C.P., Sinha, G., Ross, T. et al. (2005) Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40: 100-107.
46. Frei, C.R., Restrepo, M.I., Mortensen, E.M. and Burgess, D.S. (2006) Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 119: 865-871.
47. Fridkin, S.K., Lawton, R., Edwards, J.R., Tenover, F.C., McGowan Jr, J.E. and Gaynes, R.P. (2002) Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 8: 702-707.
48. Gajic, O., Dara, S.I., Mendez, J.L., Adesanya, A.O., Festic, E., Caples, S.M. et al. (2004) Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med 32: 1817-1824.
49. Gajic, O., Frutos-Vivar, F., Esteban, A., Hubmayr, R.D. and Anzueto, A. (2005) Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med 31: 922-926.
50. Garcia-Vidal, C., Calbo, E., Pascual, V., Ferrer, C., Quintana, S. and Garau, J. (2007) Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 30: 951-956.
51. Garcia Vazquez, E., Mensa, J., Martinez, J.A., Marcos, M.A., Puig, J., Ortega, M. et al. (2005) Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 24: 190-195.
52. Gaynes, R. and Edwards, J.R. (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41: 848-854.
53. Giamarellos-Bourboulis, E.J., Baziaka, F., Antonopoulou, A., Koutoukas, P., Kousoulas, V., Sabracos, L. et al. (2005) Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. Int J Antimicrob Agents 25: 168-172.
54. Glynn, P., Coakley, R., Kilgallen, I., Murphy, N. and O'Neill, S. (1999) Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 54: 51-55.
55. Grossman, R.F., Rotschafer, J.C. and Tan, J.S. (2005) Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 118(Suppl. 7A): 29S-38S.
56. Hageman, J.C., Uyeki, T.M., Francis, J.S., Jernigan, D.B., Wheeler, J.G., Bridges, C.B. et al. (2006) Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 12: 894-899.
57. Halley, H.J. (2000) Approaches to drug therapy, formulary, and pathway management in a large community hospital. Am J Health Syst Pharm 57(suppl.3): S17-21.
58. Hatchette, T.F., Gupta, R. and Marrie, T.J. (2000) Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 31: 1349-1356.
59. Heffelfinger, J.D., Dowell, S.F., Jorgensen, J.H., Klugman, K.P., Mabry, L.R., Musher, D.M. et al. (2000) Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 160: 1399-1408.
60. Houck, P.M., Bratzler, D.W., Nsa, W., Ma, A. and Bartlett, J.G. (2004) Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 164: 637-644.
61. Houck, P.M., MacLehose, R.F., Niederman, M.S. and Lowery, J.K. (2001) Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 119: 1420-1426.
62. JHI (2008) Institute for Healthcare Improvement: Bundle Up for Safety. Available at: http://www.ihi.org/IHI/Topics/CriticalCare/IntensiveCare/ImprovementStories/BundleUpforSafety.htm, accessed 18 January 2008.
63. Kozak, L.J., Hall, M.J. and Owings, M.F. (2002) National Hospital Discharge Survey: 2000 annual summary with detailed diagnosis and procedure data Vital & Health Statistics - Series 13: Data From the National Health Survey. 1-194.
64. Laterre, P.F., Garber, G., Levy, H., Wunderink, R., Kinasewitz, G.T., Sollet, J.P. et al. (2005) Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33: 952-961.
65. Leeper Jr, K.V. (1996) Severe community-acquired pneumonia. Semin Respir Infect 11: 96-108.
66. Lei, D., Lancaster Jr, J.R., Joshi, M.S., Nelson, S., Stoltz, D., Bagby, G.J. et al. (1997) Activation of alveolar macrophages and lung host defenses using transfer of the interferon-gamma gene. Am J Physiol 272: L852-859.
67. Leroy, O., Santre, C., Beuscart, C., Georges, H., Guery, B., Jacquier, J.M. et al. (1995) A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 21: 24-31.
68. Leroy, O., Saux, P., Bedos, J.P. and Caulin, E. (2005) Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128: 172-183.
69. Lieberman, D., Schlaeffer, F., Boldur, I., Horowitz, S., Friedman, M.G., Leiononen, M. et al. (1996) Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51: 179-184.
70. Lujan, M., Gallego, M., Fontanals, D., Mariscal, D. and Rello, J. (2004) Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med 32: 625-631.
71. Luna, C.M., Famiglietti, A., Absi, R., Videla, A.J., Nogueira, F.J., Fuenzalida, A.D. et al. (2000) Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 118: 1344-1354.
72. Mandell, L.A., Bartlett, J.G., Dowell, S.F., File Jr, T.M., Musher, D.M. and Whitney, C. (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37: 1405-1433.
73. Mandell, L.A., Marrie, T.J., Grossman, R.F., Chow, A.W. and Hyland, R.H. (2000) Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 31: 383-421.
74. Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C. et al. (2007) Infectious diseases society of America/ American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl. 2): S27-72.
75. Marrie, T.J., Carriere, K.C., Jin, Y. and Johnson, D.H. (2003) Factors associated with death among adults <55 years of age hospitalized for community-acquired pneumonia. Clin Infect Dis 36: 413-421.
76. Martinez, J.A., Horcajada, J.P., Almela, M., Marco, F., Soriano, A., Garcia, E. et al. (2003) Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36: 389-395.
77. Meehan, T.P., Fine, M.J., Krumholz, H.M., Scinto, J.D., Galusha, D.H., Mockalis, J.T. et al. (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278: 2080-2084.
78. Mehta, R. and Groth, M. (2001) Clinical application of a prognostic model for severe community-acquired pneumonia. Chest 119: 312-313.
79. Metersky, M.L., Ma, A., Houck, P.M. and Bratzler, D.W. (2007) Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 131: 466-473.
80. Moine, P., Vercken, J.B., Chevret, S., Chastang, C. and Gajdos, P. (1994) Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 105: 1487-1495.
81. Moise-Broder, P.A., Forrest, A., Birmingham, M.C. and Schentag, J.J. (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43: 925-942.
82. Moise, P.A. and Schentag, J.J. (2000) Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 16(Suppl. 1): S31-34.
83. Monton, C., Torres, A., El-Ebiary, M., Filella, X., Xaubet, A. and de la Bellacasa, J.P. (1999) Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 27: 1745-1753.
84. Mortensen, E.M., Coley, C.M., Singer, D.E., Marrie, T.J., Obrosky, D.S., Kapoor, W.N. et al. (2002) Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 162: 1059-1064.
85. Mortensen, E.M., Restrepo, M., Anzueto, A. and Pugh, J. (2004) Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 117: 726-731.
86. Mufson, M.A. and Stanek, R.J. (1999) Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 107: 34S-43S.
87. National Center for Health Statistics (NCHS) (2007) Health, United States, 2007. Hyattsville, MD: NCHS, 2007.
88. Neill, A.M., Martin, I.R., Weir, R., Anderson, R., Chereshsky, A., Epton, M.J. et al. (1996) Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 51: 1010-1016.
89. Ards Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342: 1301-1308.
90. Niederman, M.S., Mandell, L.A., Anzueto, A., Bass, J.B., Broughton, W.A., Campbell, G.D. et al. (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163: 1730-1754.
91. Niederman, M.S., McCombs, J.S., Unger, A.N., Kumar, A. and Popovian, R. (1998) The cost of treating community-acquired pneumonia. Clin Ther 20: 820-837.
92. Opal, S.M., Garber, G.E., LaRosa, S.P., Maki, D.G., Freebairn, R.C., Kinasewitz, G.T. et al. (2003) Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 37: 50-58.
93. Palmer, C.S., Zhan, C., Elixhauser, A., Halpern, M.T., Rance, L., Feagan, B.G. et al. (2000) Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 22: 250-264.
94. Parnham, M.J. (2005) Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 18: 125-131.
95. Parnham, M.J., Culic, O., Erakovic, V., Munic, V., Popovic-Grle, S., Barisic, K. et al. (2005) Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 517: 132-143.
96. Pascual, F.E., Matthay, M.A., Bacchetti, P. and Wachter, R.M. (2000) Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest 117: 503-512.
97. Pronovost, P.J., Nolan, T., Zeger, S., Miller, M. and Rubin, H. (2004) How can clinicians measure safety and quality in acute care?. Lancet 363: 1061-1067.
98. Puren, A.J., Feldman, C., Savage, N., Becker, P.J. and Smith, C. (1995) Patterns of cytokine expression in community-acquired pneumonia. Chest 107: 1342-1349.
99. Rano, A., Agusti, C., Sibila, O. and Torres, A. (2006) Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids. Curr Opin Infect Dis 19: 179-184.
100. Restrepo, M.I., Mortensen, E.M., Anzueto, A. and Pugh, J.A. (2003) Mortality in monotherapy versus combination therapy in severe community-acquired pneumonia: a systematic review. Chest 124: 190S.
101. Restrepo M.I., Mortensen E.M., Velez J.A., Frei C. and Anzueto A. (2007) A comparative study of community-acquired pneumonia patients admitted to the Ward and the Intensive Care Unit, Chest.
102. Riley, P.D., Aronsky, D. and Dean, N.C. (2004) Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 32: 2398-2402.
103. Rodriguez, A., Mendia, A., Sirvent, J.M., Barcenilla, F., de la Torre-Prados, M.V., Sole-Violan, J. et al. (2007) Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 35: 1493-1498.
104. Root, R.K., Lodato, R.F., Patrick, W., Cade, J.F., Fotheringham, N., Milwee, S. et al. (2003) Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 31: 367-373.
105. Ruiz, M., Ewig, S., Marcos, M.A., Martinez, J.A., Arancibia, F., Mensa, J. et al. (1999) Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 160: 397-405.
106. Sakoulas, G., Moise-Broder, P.A., Schentag, J., Forrest, A., Moellering Jr, R.C. and Eliopoulos, G.M. (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42: 2398-2402.
107. Salluh, J.I.F. (2006) Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med 32: 595.
108. Schultz, M.J. (2004) Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 54: 21-28.
109. Shefet, D., Robenshtok, E., Paul, M. and Leibovici, L. (2005) Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 165: 1992-2000.
110. Simpson, S.H., Marrie, T.J. and Majumdar, S.R. (2005) Do guidelines guide pneumonia practice? A systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia. Respir Care Clin N Am 11: 1-13.
111. Skrupky, L.P., Micek, S.T. and Kollef, M.H. (2007) Optimizing therapy for MRSA pneumonia. Semin Respir Crit Care Med 28: 615-623.
112. Suchyta, M.R., Dean, N.C., Narus, S. and Hadlock, C.J. (2001) Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am J Med 110: 306-309.
113. Tazi, A., Nioche, S., Chastre, J., Smiejan, J.M. and Hance, A.J. (1991) Spontaneous release of granulocyte colony-stimulating factor (G-CSF) by alveolar macrophages in the course of bacterial pneumonia and sarcoidosis: endotoxin-dependent and endotoxin-independent G-CSF release by cells recovered by bronchoalveolar lavage. Am J Respir Cell Mol Biol 4: 140-147.
114. Tejerina, E., Frutos-Vivar, F., Restrepo, M.I., Anzueto, A., Palizas, F., Gonzalez, M. et al. (2005) Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J Crit Care 20: 230-238.
115. Waterer, G.W., Somes, G.W. and Wunderink, R.G. (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161: 1837-1842.
116. Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Leven, M., Ortqvist, A. et al. (2005) Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26: 1138-1180.
117. Wunderink, R., Leeper Jr, K., Schein, R., Nelson, S., DeBoisblanc, B., Fotheringham, N. et al. (2001) Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 119: 523-529.
118. Wunderink, R.G., Rello, J., Cammarata, S.K., Croos-Dabrera, R.V. and Kollef, M.H. (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124: 1789-1797.
119. Yethon, J.A. and Whitfield, C. (2001) Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Curr Drug Targets Infect Disord 1: 91-106.
120. Yost, N.P., Bloom, S.L., Richey, S.D., Ramin, S.M. and Cunningham, F.G. (2000) An appraisal of treatment guidelines for antepartum community-acquired pneumonia. Am J Obstet Gynecol 183: 131-135.